2023
DOI: 10.1007/s00431-023-04968-4
|View full text |Cite
|
Sign up to set email alerts
|

MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 16 publications
1
7
0
Order By: Relevance
“…Given the severity of presentation in MIS-C it is not surprising that the majority ( n = 46, 63%) of our MIS-C population were admitted to the intensive care unit ( 9 ). Throughout the pandemic this remained true as the clinical severity of MIS-C was similar across Alpha, Delta and Omricon SARS-CoV-2 strains ( 33 ).…”
Section: Discussionmentioning
confidence: 93%
“…Given the severity of presentation in MIS-C it is not surprising that the majority ( n = 46, 63%) of our MIS-C population were admitted to the intensive care unit ( 9 ). Throughout the pandemic this remained true as the clinical severity of MIS-C was similar across Alpha, Delta and Omricon SARS-CoV-2 strains ( 33 ).…”
Section: Discussionmentioning
confidence: 93%
“… 7 , 21 , 22 In this context, recent studies have focused on investigating if MIS-C phenotypes may vary as well, based on SARS-CoV-2 variants. 6 , 7 , 8 , 10 , 11 , 12 , 13 Compared with EHR studies that selected patients with COVID-19-related conditions using diagnostic codes as the inclusion criteria, our study design had the advantage of patient selection using lists of patients with MIS-C validated by MIS-C experts at the site level.…”
Section: Discussionmentioning
confidence: 99%
“… 8 However, other smaller single-centre and multicentre reports from South Africa, Europe, and the U.S. found no difference in MIS-C outcomes across SAS-CoV-2 variant eras. 9 , 10 , 11 , 12 , 13 …”
Section: Introductionmentioning
confidence: 99%
“…10–12 For the most recent Omicron lineage, breakthrough infections are encountered more frequently than with any other VOCs due to substantial evolution and consequent immune evasion to available vaccines. 13 , 14 For instance, three-dose vaccination is effective against Delta infection but less effective against Omicron infection. 15 Although two doses of the BNT162b2 vaccine are associated with high protection against SARS-CoV-2 infection within 6 months, 16 primary immunization alone is not enough to protect individuals from breakthrough infection by multiple VOCs.…”
Section: Introductionmentioning
confidence: 99%